BN
BusinessAI Desk•2 views

Regeneron Drug Pricing Deal with Trump; Free Hearing Therapy Offered

Regeneron has entered into a drug pricing agreement with the Trump administration, committing to lower the cost of certain medications for U.S. consumers. Furthermore, the company announced it will offer its new gene therapy, Otarmeni, for free to eligible patients following its FDA approval. These deals are part of a broader effort by the administration to align U.S. drug pricing with international standards. The agreements also include a three-year exemption from certain tariffs. Otarmeni is a significant breakthrough treatment targeting a rare genetic cause of hearing loss.

Ad slot
Regeneron Drug Pricing Deal with Trump; Free Hearing Therapy Offered

Regeneron has agreed to lower U.S. drug prices as part of a deal with President Donald Trump, and the company will also provide a new hearing-loss gene therapy free of charge to eligible patients.

Drug Pricing Concessions and Government Agreements

The White House announced on Thursday that Regeneron reached an agreement to reduce the cost of certain drugs for American consumers. This move follows a pattern of major pharmaceutical companies making pricing concessions under agreements with the Trump administration.

These deals are part of a broader initiative aimed at linking U.S. drug prices to the lowest rates found in other developed nations, a concept referred to as a "most favored nation" effort.

Key aspects of these agreements include:

  • Pricing Adjustments: Lowering the cost of existing and new medicines for U.S. patients.
  • Tariff Exemptions: The agreements reportedly exempt participating companies from tariffs for a period of three years, potentially mitigating planned levies, such as those up to 100% on certain pharmaceutical products.
Ad slot

According to CMS deputy administrator Chris Klomp, the Trump administration has finalized 17 such deals and is continuing negotiations with additional biotech and pharmaceutical firms.

Breakthrough Gene Therapy for Hearing Loss

Regeneron's agreement was announced shortly after the Food and Drug Administration (FDA) granted approval for the company's gene therapy, Otarmeni. This therapy was approved on Thursday and received expedited clearance under the FDA's National Priority Voucher program.

  • Therapy Details: Otarmeni is a gene therapy designed to treat an ultra-rare genetic condition.
  • Mechanism: The condition stems from a mutation that prevents the body from producing a necessary protein required for hearing.
  • Significance: The treatment represents a major advancement for a specific group of patients who previously relied on cochlear implants.

Analysts previously estimated that the peak sales potential for this gene therapy could reach $130 million.

Ad slot